Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

about

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

P2860

Q28074777-4924DB54-FC41-452E-BD5D-E76B0F80535B

P2860

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Item

http://www.wikidata.org/entity/Q35636700

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Impact of JAK2(V617F) mutation ...... l, hypothesis-generating study

@ast

Impact of JAK2(V617F) mutation ...... l, hypothesis-generating study

@en

type

Item

label

Impact of JAK2(V617F) mutation ...... l, hypothesis-generating study

@ast

Impact of JAK2(V617F) mutation ...... l, hypothesis-generating study

@en

prefLabel

Impact of JAK2(V617F) mutation ...... l, hypothesis-generating study

@ast

Impact of JAK2(V617F) mutation ...... l, hypothesis-generating study

@en

P1476

Impact of JAK2(V617F) mutation ...... l, hypothesis-generating study

@en

P2093

A Marina Liberati

http://www.w3.org/2001/XMLSchema#string

Alessandra Iurlo

http://www.w3.org/2001/XMLSchema#string

Alessandro M Vannucchi

http://www.w3.org/2001/XMLSchema#string

Heinrich Achenbach

http://www.w3.org/2001/XMLSchema#string

Jonathan Smith

http://www.w3.org/2001/XMLSchema#string

Marco Gobbi

http://www.w3.org/2001/XMLSchema#string

Mariella D'Adda

http://www.w3.org/2001/XMLSchema#string

Nicola Cascavilla

http://www.w3.org/2001/XMLSchema#string

Paul Wilde

http://www.w3.org/2001/XMLSchema#string

Rajmonda Fjerza

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

P304

2687-2694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S79576

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26028965

http://www.w3.org/2001/XMLSchema#string

P932

4441358

http://www.w3.org/2001/XMLSchema#string

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

about

P2860

P2860

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932